Citadel Advisors’s Global Blood Therapeutics, Inc. GBT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-15,500
| Closed | -$1.06M | – | 16075 |
|
|
2022
Q3 | $1.06M | Sell |
15,500
-42,000
| -73% | -$2.32M | ﹤0.01% | 6875 |
|
|
2022
Q2 | $1.84M | Buy |
57,500
+8,700
| +18% | +$255K | ﹤0.01% | 5714 |
|
|
2022
Q1 | $1.69M | Sell |
48,800
-25,200
| -34% | -$753K | ﹤0.01% | 6467 |
|
|
2021
Q4 | $2.17M | Sell |
74,000
-12,100
| -14% | -$375K | ﹤0.01% | 6049 |
|
|
2021
Q3 | $2.19M | Buy |
86,100
+31,100
| +57% | +$914K | ﹤0.01% | 6118 |
|
|
2021
Q2 | $1.93M | Sell |
55,000
-40,300
| -42% | -$1.57M | ﹤0.01% | 6714 |
|
|
2021
Q1 | $3.88M | Sell |
95,300
-59,400
| -38% | -$2.73M | ﹤0.01% | 4834 |
|
|
2020
Q4 | $6.7M | Buy |
154,700
+68,200
| +79% | +$3.36M | ﹤0.01% | 3196 |
|
|
2020
Q3 | $4.77M | Sell |
86,500
-8,800
| -9% | -$559K | ﹤0.01% | 3237 |
|
|
2020
Q2 | $6.02M | Buy |
95,300
+4,100
| +4% | +$281K | ﹤0.01% | 2833 |
|
|
2020
Q1 | $4.66M | Sell |
91,200
-75,200
| -45% | -$5.04M | ﹤0.01% | 2812 |
|
|
2019
Q4 | $13.2M | Buy |
166,400
+52,700
| +46% | +$3.12M | 0.01% | 1911 |
|
|
2019
Q3 | $5.52M | Sell |
113,700
-110,900
| -49% | -$5.78M | ﹤0.01% | 2975 |
|
|
2019
Q2 | $11.8M | Buy |
224,600
+187,600
| +507% | +$10.8M | 0.01% | 1976 |
|
|
2019
Q1 | $1.96M | Sell |
37,000
-52,800
| -59% | -$2.59M | ﹤0.01% | 4503 |
|
|
2018
Q4 | $3.69M | Buy |
89,800
+9,800
| +12% | +$367K | ﹤0.01% | 3236 |
|
|
2018
Q3 | $3.04M | Sell |
80,000
-73,700
| -48% | -$3.26M | ﹤0.01% | 3710 |
|
|
2018
Q2 | $6.95M | Buy |
153,700
+111,100
| +261% | +$5.06M | ﹤0.01% | 2348 |
|
|
2018
Q1 | $2.06M | Buy |
+42,600
| New | +$2.38M | ﹤0.01% | 3691 |
|
|
2017
Q3 | – | Sell |
-20,700
| Closed | -$566K | – | 8228 |
|
|
2017
Q2 | $566K | Sell |
20,700
-12,500
| -38% | -$372K | ﹤0.01% | 4942 |
|
|
2017
Q1 | $1.22M | Buy |
+33,200
| New | +$836K | ﹤0.01% | 3727 |
|
|
2016
Q3 | – | Sell |
-10,800
| Closed | -$179K | – | 7948 |
|
|
2016
Q2 | $179K | Buy |
+10,800
| New | +$218K | ﹤0.01% | 5910 |
|
Other funds holding GBT
Citadel Advisors's GBT Position: Q4 2022 in Review
Citadel Advisors sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 51,397 shares — an estimated $3.5M sold.
Citadel Advisors first reported a position in GBT in Q3 2016 and held it in 24 quarters. The position peaked at $68.1M in Q1 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.
- Citadel Advisors reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
- Citadel Advisors sold 51,397 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $3.5M.
- Citadel Advisors first reported a position in Global Blood Therapeutics, Inc. in Q3 2016 and held it in 24 quarters.
- Citadel Advisors's Global Blood Therapeutics, Inc. position peaked at $68.1M in Q1 2022.
- 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.
Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.